19-12-2013 дата публикации
Номер: US20130336975A1
Автор:
Akatsuka Corinne C.,
Billgren Jens,
Chang Betty Yu-Ching,
Dutzar Benjamin H.,
Fan Pei,
Garcia-Martinez Leon F.,
Kovacevich Brian R.,
Latham John A.,
McNeill Patricia Dianne,
Mitchell Danielle M.,
Ojala Ethan W.,
Stewart Erica A.
Принадлежит:
The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF. 1119-. (canceled)120. An anti-human NGF antibody or antibody fragment thereof which specifically binds to the same or overlapping epitope(s) and/or competes for binding to the same or overlapping epitope(s) on an intact NGF polypeptide or fragment thereof as an anti-human NGF antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , and Ab21 or is an antibody or antibody fragment comprising the same CDRs as any of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab6 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 , Ab14 , Ab15 , Ab16 , Ab17 , Ab18 , Ab19 , Ab20 , and Ab21.121. The antibody of claim 120 , wherein:{'sub': '2', '(i) said antibody fragment is selected from an Fab fragment, an Fab′ fragment, scFv, or an F(ab′)fragment;'}{'sub': H', 'L, '(ii) said antibody or fragment comprises a Vpolypeptide at least 90% identical to one selected from those in SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 153, 163, 173, 183, 193, or 402 and/or Vpolypeptide sequence at least 90% identical to one selected from: SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111 ...
Подробнее
